Reports

- Global Locations -

Headquarters

Future Market Insights, Inc.

Christiana Corporate, 200
Continental Drive, Suite 401,
Newark, Delaware - 19713,
United States

T: +1-347-918-3531

Americas

Future Market Insights, Inc.

616 Corporate Way, Suite 2-9018,
Valley Cottage, NY 10989, United States

MEA

Future Market Insights

1602-6 Jumeirah Bay X2 Tower, Plot No: JLT-PH2-X2A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates

Europe

Future Market Insights

3rd Floor, 207 Regent Street,
W1B 3HH London
United Kingdom

T: + 44 (0) 20 8123 9659

Asia Pacific

Future Market Insights

IndiaLand Global Tech Park, Unit UG-1, Behind Grand HighStreet, Phase 1, Hinjawadi, MH, Pune – 411057, India

Drug-Induced Dyskinesia Market Snapshot (2023 to 2033)

The global drug-induced dyskinesia market is expected to be worth US$ 399.8 Million in the fiscal year 2023, which rose up from US$ 382 Million in the fiscal year 2022. From 2023 to 2033, the global market is expected to grow at a steady 4.25% CAGR, reaching a value of US$ 620.2 Million by the end of 2033.

Drug-induced dyskinesia is an uncommon neurological condition caused by the long-term use of antipsychotic medicines that act on dopamine receptors. Due to a number of factors, including a rise in the incidence of drug-induced dyskinesia, a greater number of unmet therapeutic interventions, and the anticipated introduction of several pipeline drugs, it is predicted that the market for drugs used to treat drug-induced dyskinesia will experience significant market expansion over the course of the forecast period.

Despite the many medications used to treat drug-induced dyskinesia, the US FDA has only given its approval to Deutetrabenazine and Valbenazine so far. Other medications are also used to treat the symptoms of drug-induced dyskinesia, including botulinum toxin, benzodiazepines, dopamine-depleting medicines, amantadine, and calcium channel blockers, among others.

Drug-induced dyskinesia causes uncontrollable or spontaneous movements such as twitching, thrusting, and grimacing. Even though a disease may last a lifetime, early treatment can stop symptoms from getting worse and, in many circumstances, even reverse them. Drug-induced dyskinesia may be minor, moderate, or severe, depending on the symptoms. In light to moderate cases of drug-induced dyskinesia, the face, lips, tongue, and jaw muscles are tense and jerking; typical actions include smacking, blinking, or puckering lips, and thrusting the tongue out. People with mild signs of drug-induced dyskinesia frequently experience uncontrollable movement in their arms and legs. Hence, at present, various manufacturers are aimed at developing drugs and other solutions that would cure the symptoms of this disease and prevent the person from getting it again.

Attributes Details
Anticipated Base Year Value (2022) US$ 382 Million
Expected Market Value (2023) US$ 399.8 Million
Projected Forecast Value (2033) US$ 620.2 Million
Global Growth Rate (2023 to 2033) 4.25%
CAGR of North America (2023) 4.3%
CAGR of APAC (2023 to 2033) 3.5%
Prominent Players in The Global Market
  • Teva Pharmaceuticals
  • Neurocrine Bioscience
  • Sun Pharmaceutical Industries Ltd
  • SteriMax Inc.
  • Lannett Co Inc
  • Adamas Pharmaceuticals, Inc
  • Sanis
  • AbbVie Inc.
  • Dystonia Medical Research Foundation
  • Pharos: Illuminating the Druggable Genome

Don't pay for what you don't need

Customize your report by selecting specific countries or regions and save 30%!

2017 to 2022 Drug-Induced Dyskinesia Market Demand Analysis Vs. Forecast 2023 to 2033

The global drug-induced dyskinesia market grew at a CAGR of 3.1% from 2017 to 2022, as per Future Market Insights, a provider of market research and competitive intelligence. Due to the growing frequency of drug-induced dyskinesia linked to an increased incidence of neurologic diseases such as schizophrenia, bipolar disorder, and Alzheimer's disease, the worldwide market for drug-induced dyskinesia is anticipated to post a consistent revenue CAGR in 2021.

Additionally, rising Research and Development efforts, elevated awareness, technical advancements, a robust product pipeline, a desire for more potent therapies, and innovation in treatment are predicted to drive market expansion throughout the course of the projection period.

Such factors are expected to boost the global sales of drug-induced dyskinesia solutions. As a result, the global drug-induced dyskinesia market is expected to forecast a CAGR of over 4% from 2023 to 2033.

Prominent Growth Drivers Influencing drug-induced dyskinesia market

Increasing cases of schizophrenic as well as other neurological diseases to boost the demand

Dyskinesia has been proven to be much more prevalent among patients who suffer from diseases like schizophrenia and other neurological disorders. Patients with schizophrenia who use antipsychotic medications for a prolonged period of time have a substantial risk of developing drug-induced dyskinesia. As a result, an increasing number of antipsychotic medications come with a significant risk, which encourages the market's expansion. For instance, according to a report from the World Health Organization published in January 2022, schizophrenia affects 24 million people worldwide, or 0.32%, out of which a ratio of 1 in 222 people (0.45%) were adults.

Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 individuals throughout the world will be 60 years of age or older by 2030, increasing the likelihood that they may acquire Parkinson's and Alzheimer's disease. Thus, it is anticipated that the pool demographic for drug-induced dyskinesia would increase as Alzheimer's disease prevalence rises, increasing the demand for treatment and potentially stimulating the market. Such factors are sure to propel the market for drug-induced dyskinesia during the forecast period.

Various neuroleptic drugs cause dyskinesia among the patients

Long-term neuroleptic medication usage raises the likelihood of drug-induced dyskinesia and hence boosts the market for drug-induced dyskinesia medicines. When used for a few weeks or longer, specific medications that disrupt dopamine receptors within the brain can result in drug-induced dyskinesia. Antipsychotics, antiemetics, and antidepressants are some of these medications.

Schizophrenia is treated with typical antipsychotic medications, commonly referred to as first-generation antipsychotic medications. Some of these medications also address other disorders including nausea and vomiting. However, when used over an extended length of time, these medications cause dyskinesia in the patients.

Since a side effect of neuroleptic medications is drug-induced dyskinesia, the frequency of neurological conditions including Alzheimer's disease, schizophrenia, and bipolar disorder is rising, and so is the need for antipsychotic medications.

Such factors are expected to accelerate the demand for drug-induced dyskinesia during the forecast period.

Sabyasachi Ghosh
Sabyasachi Ghosh

Principal Consultant

Talk to Analyst

Find your sweet spots for generating winning opportunities in this market.

What Could Possibly Hinder Drug-Induced Dyskinesia Market Demand? 

Clonidine-induced hypotension and other relevant factors will impede the growth

The market for medications that produce drug-induced dyskinesia is anticipated to suffer from adverse effects such as clonidine-induced hypotension as well as sedation. These elements are recognized to lessen patients' dyskinesia symptoms as well as effectively treat their illnesses for an extended length of time.

The market is also anticipated to be hampered by high treatment costs, poor diagnosis rates, societal stigma, a shortage of qualified healthcare professionals, and the relatively high price of a clinical trial over the projection period.

Region-wise Analysis 

What is the outlook of the North American drug-induced dyskinesia market?

High prevalence of neuropathic diseases to boost the regional demand

North America is predicted to hold the dominant market share of 41% revenue share in 2023 and is the fastest-growing market for drug-induced dyskinesia, with a dominant 4.3% CAGR from 2023 to 2033.

A large portion of the global market for drug-induced dyskinesia treatments is anticipated to be accounted for by North America, owing to factors such as an aging population, a higher incidence of schizophrenia, rising dyskinesia awareness, rising healthcare costs, and developed healthcare infrastructure. As the world's population ages, various neurological illnesses will emerge, necessitating the use of antipsychiatric medications. As a result, these groups are more likely to get certain illnesses. In May 2021, the National Alliance on Mental Health reported that 1.5 million Americans, or 0.25% to 0.64% of the population, were living with schizophrenia.

Thus, the high prevalence of the condition among the elderly population of nations across North America is expected to increase demand for the development of therapeutic medications, resulting in the market's expansion. A further factor supporting the growth of the drug-induced dyskinesia treatment market in this area is the association of this illness with specific patient pools such as individuals treated for schizophrenia as well as bipolar disorder in this area.

What can be expected from the APAC market for drug-induced dyskinesia?

Large patient pool and more research and awareness programs to propel the sales

During the forecast period, the APAC market for drug-induced dyskinesia is expected to garner a steady CAGR of 3.5%. But at the time, this market is presently acquiring a 31% market share in the global drug-induced dyskinesia market.

Due to a larger patient pool, more involvement in research and public awareness campaigns about drug-induced dyskinesia therapy, and enhanced public health awareness, the Asia Pacific area is anticipated to develop at the quickest rate throughout the projection period.

The drug-induced dyskinesia APAC market is also anticipated to develop throughout the projected period as a result of an expanding patient base for neuroleptic illnesses including bipolar disorder, schizophrenia, and others as well as improved healthcare infrastructure and greater healthcare spending.

Get the data you need at a Fraction of the cost

Personalize your report by choosing insights you need
and save 40%!

Category-wise Insights 

Which product type segment is expected to gain traction from 2023 to 2033?

The VMAT 2 segment will gain the dominant market share

Over the course of the forecast period, the VMAT 2 segment by drug class is anticipated to occupy a significant share of the global drug-induced dyskinesia market. In 2023, this category is anticipated to dominate with a 46% revenue share.

VMAT2 inhibitors are drugs that produce dopamine depletion in nerve endings and are employed to treat chorea caused by neurodegenerative disorders (like Huntington's chorea) or dyskinesias caused by neuroleptic medicines. With more neurological disorders and more people being prescribed antipsychotic medications, VMAT is predicted to have healthy development in the next few years. According to the research article Monoamine Oxidase-B Inhibitors for the Treatment of Parkinson's Disease: Past, Present, and Future released in February 2022, there are an estimated 6.1 million people worldwide who have Parkinson's disease. The prevalence rises with age, reaching 1% to 3% in people over 65.

Additionally, according to figures released by the World Health Organization (WHO) in October 2021, 1 in 6 persons worldwide would be 60 years of age or older by the year 2030. Parkinson's therapy is linked to drug-induced dyskinesia, and it is anticipated that the prevalence of the illness would increase during the projection period, increasing demand for the possible treatment and driving segment growth. Such factors are expected to accelerate the growth prospects for drug-induced dyskinesia from 2023 to 2033.

What would be the outlook of the sales channel segments?

The hospital's segment will become more significant from 2023 to 2033

On the basis of the sales channel, the most dominant segment is the hospital segment, which is expected to occupy a global market share of 32% from 2023 to 2033.

The hospital segment is expected to acquire the dominant position on the basis of channel type. This can be attributed to the increasing number of elderly patients admitted to hospitals. When it comes to the elderly, no one wants to take risks and keep the patient at home, particularly in case of any neurological disorder. In hospitals, the patients can be monitored effectively 24X7 and given the medicines at the apt time they need. Hence, with such advantages, the segment is expected to witness immense growth during the forecast period.

Start-up Scenario

The new companies are aimed at developing their products with enhanced safety features and new technology to make the products stand out in the global market.

  • The UK-based firm, ClearSky Medical Diagnostics, specializes in medical equipment for neurodegenerative disease diagnosis and monitoring. Innovative solutions for at-home dyskinesia management, smart gloves for differentiated neurodegenerative disease diagnosis, patient visuospatial aptitude testing, and Parkinson's symptoms monitoring are among the products offered by the firm. These tools offer immediate input to facilitate the management of neurodegenerative diseases.
  • Founded in the year 2013 and based out of the USA, MentiNova is working on medicines for Parkinson's disease sufferers. The business is repurposing an authorized medication to treat Parkinson's sufferers' L-Dopa Induced Dyskinesia.

Competitive Landscape 

Some of the prominent players in the global market for drug-induced dyskinesia are:

  • Teva Pharmaceuticals
  • Neurocrine Bioscience
  • Sun Pharmaceutical Industries Ltd
  • SteriMax Inc.
  • Lannett Co Inc
  • Adamas Pharmaceuticals, Inc
  • Sanis
  • AbbVie Inc.
  • Dystonia Medical Research Foundation
  • Pharos Illuminating the Druggable Genome

Some of the prominent developments of the key players in the market are:

  • In 2021, Teva Pharmaceuticals, a corporation of Teva Pharmaceutical Industries Ltd. based out of the USA, published the findings of a post-hoc assessment of a three-year open-label extension (OLE) research investigating safety and efficacy endpoints for the usage of AUSTEDO (Deutetrabenazine) tablets among the younger (55 years) and older (55 years) patients with drug-induced dyskinesia. This study adds to the understanding of AUSTEDO as a medication that may assist relieve uncontrollable movements in adults but is more convincing when it comes to treating elderly people.
  • Neurocrine Bioscience established a drug-induced dyskinesia awareness week initiative in July 2018 due to the emotional and social effects that drug-induced dyskinesia may have on people's mental health.

Key Segments Covered In The Drug-Induced Dyskinesia Market Report 

Drug-Induced Dyskinesia Market By Drug Class:

  • Dopamine-Depleting Medications
  • Vmat2 Inhibitors
  • Gaba Receptor Agonist Medications
  • Anticholinergic Medications

Drug-Induced Dyskinesia Market By End User:

  • Hospitals
  • Clinics
  • Others

Drug-Induced Dyskinesia Market By Region :

  • North America
  • Latin America
  • Europe
  • Asia-Pacific (APAC)
  • Middle East & Africa (MEA)

Frequently Asked Questions

At what rate did the drug-induced dyskinesia market flourish from 2017 to 2022?

During the historical period of 2017 to 2022, the drug-induced dyskinesia market grew at a CAGR of 3.1%.

What will be the growth rate of the global drug-induced dyskinesia market during the forecast period?

The global drug-induced dyskinesia market is predicted to rise with a steady 4.25% CAGR from 2023 to 2033.

What is the present market value of the drug-induced dyskinesia market?

The global drug-induced dyskinesia market is currently worth more than US$ 382 Million.

What will be the projected market size of the drug-induced dyskinesia market by 2033?

By 2033, the global drug-induced dyskinesia market is projected to reach a market size of US$ 620.2 Million.

Which segment is expected to dominate the global drug-induced dyskinesia market during 2023?

In 2023, the VMAT 2 segment by drug class type is anticipated to dominate with a 46% revenue share.

What will be the outlook of the other segment during the forecast period?

The hospitals segment by end user will occupy the second largest segment during the forecast period with a 32% market share in 2023.

How is the North American drug-induced dyskinesia market projected to grow during 2023 to 2033?

The North American region is predicted to grow with a steady CAGR of 4.3% from 2023 to 2033.

What is the outlook of the APAC drug-induced dyskinesia market during 2023?

The APAC drug-induced dyskinesia market is expected to grow with a steady CAGR of 3.5% from 2023 to 2033.

Table of Content

1. Executive Summary | Drug-Induced Dyskinesia Market

    1.1. Global Market Outlook

    1.2. Demand-side Trends

    1.3. Supply-side Trends

    1.4. Technology Roadmap Analysis

    1.5. Analysis and Recommendations

2. Market Overview

    2.1. Market Coverage / Taxonomy

    2.2. Market Definition / Scope / Limitations

3. Market Background

    3.1. Market Dynamics

        3.1.1. Drivers

        3.1.2. Restraints

        3.1.3. Opportunity

        3.1.4. Trends

    3.2. Scenario Forecast

        3.2.1. Demand in Optimistic Scenario

        3.2.2. Demand in Likely Scenario

        3.2.3. Demand in Conservative Scenario

    3.3. Opportunity Map Analysis

    3.4. Investment Feasibility Matrix

    3.5. PESTLE and Porter’s Analysis

    3.6. Regulatory Landscape

        3.6.1. By Key Regions

        3.6.2. By Key Countries

    3.7. Regional Parent Market Outlook

4. Global Market Analysis 2017 to 2022 and Forecast, 2023 to 2033

    4.1. Historical Market Size Value (US$ Million) Analysis, 2017 to 2022

    4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033

        4.2.1. Y-o-Y Growth Trend Analysis

        4.2.2. Absolute $ Opportunity Analysis

5. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class

    5.1. Introduction / Key Findings

    5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2017 to 2022

    5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033

        5.3.1. Dopamine-Depleting Medications

        5.3.2. VMAT2 inhibitors

        5.3.3. GABA Receptor agonist medications

        5.3.4. Anticholinergic Medications

    5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2017 to 2022

    5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033

6. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By End User

    6.1. Introduction / Key Findings

    6.2. Historical Market Size Value (US$ Million) Analysis By End User, 2017 to 2022

    6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033

        6.3.1. Hospitals

        6.3.2. Clinics

        6.3.3. Others

    6.4. Y-o-Y Growth Trend Analysis By End User, 2017 to 2022

    6.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033

7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Region

    7.1. Introduction

    7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2017 to 2022

    7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033

        7.3.1. North America

        7.3.2. Latin America

        7.3.3. Europe

        7.3.4. South Asia & Pacific

        7.3.5. East Asia

        7.3.6. Middle East and Africa (MEA)

    7.4. Market Attractiveness Analysis By Region

8. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        8.2.1. By Country

            8.2.1.1. United States of America

            8.2.1.2. Canada

        8.2.2. By Drug Class

        8.2.3. By End User

    8.3. Market Attractiveness Analysis

        8.3.1. By Country

        8.3.2. By Drug Class

        8.3.3. By End User

    8.4. Key Takeaways

9. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        9.2.1. By Country

            9.2.1.1. Brazil

            9.2.1.2. Mexico

            9.2.1.3. Rest of Latin America

        9.2.2. By Drug Class

        9.2.3. By End User

    9.3. Market Attractiveness Analysis

        9.3.1. By Country

        9.3.2. By Drug Class

        9.3.3. By End User

    9.4. Key Takeaways

10. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        10.2.1. By Country

            10.2.1.1. Germany

            10.2.1.2. United Kingdom

            10.2.1.3. France

            10.2.1.4. Spain

            10.2.1.5. Italy

            10.2.1.6. Rest of Europe

        10.2.2. By Drug Class

        10.2.3. By End User

    10.3. Market Attractiveness Analysis

        10.3.1. By Country

        10.3.2. By Drug Class

        10.3.3. By End User

    10.4. Key Takeaways

11. South Asia & Pacific Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        11.2.1. By Country

            11.2.1.1. India

            11.2.1.2. Malaysia

            11.2.1.3. Singapore

            11.2.1.4. Thailand

            11.2.1.5. Australia

            11.2.1.6. New Zealand

            11.2.1.7. Rest of South Asia & Pacific

        11.2.2. By Drug Class

        11.2.3. By End User

    11.3. Market Attractiveness Analysis

        11.3.1. By Country

        11.3.2. By Drug Class

        11.3.3. By End User

    11.4. Key Takeaways

12. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        12.2.1. By Country

            12.2.1.1. China

            12.2.1.2. Japan

            12.2.1.3. South Korea

        12.2.2. By Drug Class

        12.2.3. By End User

    12.3. Market Attractiveness Analysis

        12.3.1. By Country

        12.3.2. By Drug Class

        12.3.3. By End User

    12.4. Key Takeaways

13. MEA Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Country

    13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2017 to 2022

    13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033

        13.2.1. By Country

            13.2.1.1. GCC Countries

            13.2.1.2. South Africa

            13.2.1.3. Israel

            13.2.1.4. Rest of MEA

        13.2.2. By Drug Class

        13.2.3. By End User

    13.3. Market Attractiveness Analysis

        13.3.1. By Country

        13.3.2. By Drug Class

        13.3.3. By End User

    13.4. Key Takeaways

14. Key Countries Market Analysis

    14.1. United States of America

        14.1.1. Pricing Analysis

        14.1.2. Market Share Analysis, 2022

            14.1.2.1. By Drug Class

            14.1.2.2. By End User

    14.2. Canada

        14.2.1. Pricing Analysis

        14.2.2. Market Share Analysis, 2022

            14.2.2.1. By Drug Class

            14.2.2.2. By End User

    14.3. Brazil

        14.3.1. Pricing Analysis

        14.3.2. Market Share Analysis, 2022

            14.3.2.1. By Drug Class

            14.3.2.2. By End User

    14.4. Mexico

        14.4.1. Pricing Analysis

        14.4.2. Market Share Analysis, 2022

            14.4.2.1. By Drug Class

            14.4.2.2. By End User

    14.5. Germany

        14.5.1. Pricing Analysis

        14.5.2. Market Share Analysis, 2022

            14.5.2.1. By Drug Class

            14.5.2.2. By End User

    14.6. United Kingdom

        14.6.1. Pricing Analysis

        14.6.2. Market Share Analysis, 2022

            14.6.2.1. By Drug Class

            14.6.2.2. By End User

    14.7. France

        14.7.1. Pricing Analysis

        14.7.2. Market Share Analysis, 2022

            14.7.2.1. By Drug Class

            14.7.2.2. By End User

    14.8. Spain

        14.8.1. Pricing Analysis

        14.8.2. Market Share Analysis, 2022

            14.8.2.1. By Drug Class

            14.8.2.2. By End User

    14.9. Italy

        14.9.1. Pricing Analysis

        14.9.2. Market Share Analysis, 2022

            14.9.2.1. By Drug Class

            14.9.2.2. By End User

    14.10. India

        14.10.1. Pricing Analysis

        14.10.2. Market Share Analysis, 2022

            14.10.2.1. By Drug Class

            14.10.2.2. By End User

    14.11. Malaysia

        14.11.1. Pricing Analysis

        14.11.2. Market Share Analysis, 2022

            14.11.2.1. By Drug Class

            14.11.2.2. By End User

    14.12. Singapore

        14.12.1. Pricing Analysis

        14.12.2. Market Share Analysis, 2022

            14.12.2.1. By Drug Class

            14.12.2.2. By End User

    14.13. Thailand

        14.13.1. Pricing Analysis

        14.13.2. Market Share Analysis, 2022

            14.13.2.1. By Drug Class

            14.13.2.2. By End User

    14.14. Australia

        14.14.1. Pricing Analysis

        14.14.2. Market Share Analysis, 2022

            14.14.2.1. By Drug Class

            14.14.2.2. By End User

    14.15. New Zealand

        14.15.1. Pricing Analysis

        14.15.2. Market Share Analysis, 2022

            14.15.2.1. By Drug Class

            14.15.2.2. By End User

    14.16. China

        14.16.1. Pricing Analysis

        14.16.2. Market Share Analysis, 2022

            14.16.2.1. By Drug Class

            14.16.2.2. By End User

    14.17. Japan

        14.17.1. Pricing Analysis

        14.17.2. Market Share Analysis, 2022

            14.17.2.1. By Drug Class

            14.17.2.2. By End User

    14.18. South Korea

        14.18.1. Pricing Analysis

        14.18.2. Market Share Analysis, 2022

            14.18.2.1. By Drug Class

            14.18.2.2. By End User

    14.19. GCC Countries

        14.19.1. Pricing Analysis

        14.19.2. Market Share Analysis, 2022

            14.19.2.1. By Drug Class

            14.19.2.2. By End User

    14.20. South Africa

        14.20.1. Pricing Analysis

        14.20.2. Market Share Analysis, 2022

            14.20.2.1. By Drug Class

            14.20.2.2. By End User

    14.21. Israel

        14.21.1. Pricing Analysis

        14.21.2. Market Share Analysis, 2022

            14.21.2.1. By Drug Class

            14.21.2.2. By End User

15. Market Structure Analysis

    15.1. Competition Dashboard

    15.2. Competition Benchmarking

    15.3. Market Share Analysis of Top Players

        15.3.1. By Regional

        15.3.2. By Drug Class

        15.3.3. By End User

16. Competition Analysis

    16.1. Competition Deep Dive

        16.1.1. Neurocrine Biosciences, Inc

            16.1.1.1. Overview

            16.1.1.2. Product Portfolio

            16.1.1.3. Profitability by Market Segments

            16.1.1.4. Sales Footprint

            16.1.1.5. Strategy Overview

                16.1.1.5.1. Marketing Strategy

        16.1.2. Teva Pharmaceutical Industries Ltd

            16.1.2.1. Overview

            16.1.2.2. Product Portfolio

            16.1.2.3. Profitability by Market Segments

            16.1.2.4. Sales Footprint

            16.1.2.5. Strategy Overview

                16.1.2.5.1. Marketing Strategy

        16.1.3. Sun Pharmaceutical Industries Ltd

            16.1.3.1. Overview

            16.1.3.2. Product Portfolio

            16.1.3.3. Profitability by Market Segments

            16.1.3.4. Sales Footprint

            16.1.3.5. Strategy Overview

                16.1.3.5.1. Marketing Strategy

        16.1.4. SteriMax Inc.

            16.1.4.1. Overview

            16.1.4.2. Product Portfolio

            16.1.4.3. Profitability by Market Segments

            16.1.4.4. Sales Footprint

            16.1.4.5. Strategy Overview

                16.1.4.5.1. Marketing Strategy

        16.1.5. Lannett Co Inc

            16.1.5.1. Overview

            16.1.5.2. Product Portfolio

            16.1.5.3. Profitability by Market Segments

            16.1.5.4. Sales Footprint

            16.1.5.5. Strategy Overview

                16.1.5.5.1. Marketing Strategy

        16.1.6. Adamas Pharmaceuticals, Inc

            16.1.6.1. Overview

            16.1.6.2. Product Portfolio

            16.1.6.3. Profitability by Market Segments

            16.1.6.4. Sales Footprint

            16.1.6.5. Strategy Overview

                16.1.6.5.1. Marketing Strategy

        16.1.7. Sanis

            16.1.7.1. Overview

            16.1.7.2. Product Portfolio

            16.1.7.3. Profitability by Market Segments

            16.1.7.4. Sales Footprint

            16.1.7.5. Strategy Overview

                16.1.7.5.1. Marketing Strategy

        16.1.8. AbbVie Inc.

            16.1.8.1. Overview

            16.1.8.2. Product Portfolio

            16.1.8.3. Profitability by Market Segments

            16.1.8.4. Sales Footprint

            16.1.8.5. Strategy Overview

                16.1.8.5.1. Marketing Strategy

        16.1.9. Dystonia Medical Research Foundation

            16.1.9.1. Overview

            16.1.9.2. Product Portfolio

            16.1.9.3. Profitability by Market Segments

            16.1.9.4. Sales Footprint

            16.1.9.5. Strategy Overview

                16.1.9.5.1. Marketing Strategy

        16.1.10. Pharos: Illuminating the Druggable Genome

            16.1.10.1. Overview

            16.1.10.2. Product Portfolio

            16.1.10.3. Profitability by Market Segments

            16.1.10.4. Sales Footprint

            16.1.10.5. Strategy Overview

                16.1.10.5.1. Marketing Strategy

17. Assumptions & Acronyms Used

18. Research Methodology

Recommendations

Healthcare

Therapeutic Drug Monitoring Market

Published : April 2024

Healthcare

Injectable Drug Delivery Market

Published : April 2024

Healthcare

Breast Cancer Drug Market

Published : July 2023

Healthcare

Cloud Based Drug Discovery Platform Market

Published : October 2022

Explore Healthcare Insights

View Reports

Drug-Induced Dyskinesia Market